Neovacs S.A. (ALNEV.PA)

EUR 1.11

(-11.15%)

EBITDA Summary of Neovacs S.A.

  • Neovacs S.A.'s latest annual EBITDA in 2023 was -8.44 Million EUR , down -7.42% from previous year.
  • Neovacs S.A.'s latest quarterly EBITDA in 2024 Q2 was -31.34 Million EUR , down 0.0% from previous quarter.
  • Neovacs S.A. reported an annual EBITDA of -3.6 Million EUR in 2022, up 18.89% from previous year.
  • Neovacs S.A. reported an annual EBITDA of -10.37 Million EUR in 2021, down -125.15% from previous year.
  • Neovacs S.A. reported a quarterly EBITDA of -3.6 Million EUR for 2023 Q2, down 0.0% from previous quarter.
  • Neovacs S.A. reported a quarterly EBITDA of N/A for 2023 FY, down -7.42% from previous quarter.

Annual EBITDA Chart of Neovacs S.A. (2023 - 2009)

Historical Annual EBITDA of Neovacs S.A. (2023 - 2009)

Year EBITDA EBITDA Growth
2023 -8.44 Million EUR -7.42%
2022 -3.6 Million EUR 18.89%
2021 -10.37 Million EUR -125.15%
2020 -4.62 Million EUR 58.15%
2019 -9.13 Million EUR 36.89%
2018 -13.08 Million EUR 31.49%
2017 -18.29 Million EUR -10.29%
2016 -17.19 Million EUR -53.43%
2015 -7.13 Million EUR -16.9%
2014 -9.6 Million EUR -19.97%
2013 -7.82 Million EUR 3.46%
2012 -8.12 Million EUR 15.79%
2011 -9.54 Million EUR 0.61%
2010 -9.9 Million EUR -18.3%
2009 -8.33 Million EUR 0.0%

Peer EBITDA Comparison of Neovacs S.A.

Name EBITDA EBITDA Difference
ABIONYX Pharma SA -3.29 Million EUR -156.825%
ABIVAX Société Anonyme -133.2 Million EUR 93.657%
Adocia SA -22.73 Million EUR 62.83%
Aelis Farma SA -6.34 Million EUR -33.127%
Biophytis S.A. -13.8 Million EUR 38.789%
Advicenne S.A. -6.24 Million EUR -35.323%
genOway Société anonyme 6.35 Million EUR 233.048%
IntegraGen SA -52.5 Thousand EUR -15993.454%
Medesis Pharma S.A. -3.84 Million EUR -119.761%
NFL Biosciences SA -4.04 Million EUR -108.667%
Plant Advanced Technologies SA 72.53 Thousand EUR 11749.726%
Quantum Genomics Société Anonyme -2.87 Million EUR -194.053%
Sensorion SA -22.31 Million EUR 62.133%
Theranexus Société Anonyme -7.38 Million EUR -14.38%
TME Pharma N.V. -5.07 Million EUR -66.592%
Valbiotis SA -6.95 Million EUR -21.489%
TheraVet SA -517.33 Thousand EUR -1533.28%
Valerio Therapeutics Société anonyme -18.91 Million EUR 55.331%
argenx SE -199.5 Million EUR 95.765%
BioSenic S.A. -6.79 Million EUR -24.331%
Celyad Oncology SA -7.76 Million EUR -8.844%
DBV Technologies S.A. -79.53 Million EUR 89.376%
Galapagos NV 51.03 Million EUR 116.556%
Genfit S.A. -28.05 Million EUR 69.878%
GeNeuro SA -14.31 Million EUR 40.985%
Hyloris Pharmaceuticals SA -14.98 Million EUR 43.594%
Innate Pharma S.A. -7.57 Million EUR -11.501%
Inventiva S.A. -101.84 Million EUR 91.704%
MaaT Pharma SA -19.74 Million EUR 57.196%
MedinCell S.A. -20.04 Million EUR 57.849%
Nanobiotix S.A. -34.01 Million EUR 75.162%
Onward Medical N.V. -35.23 Million EUR 76.019%
Oryzon Genomics S.A. -4.43 Million EUR -90.59%
OSE Immunotherapeutics SA -23.26 Million EUR 63.683%
Oxurion NV -16.72 Million EUR 49.492%
Pharming Group N.V. 4.98 Million EUR 269.637%
Poxel S.A. -12.17 Million EUR 30.622%
GenSight Biologics S.A. -21.73 Million EUR 61.116%
Transgene SA -27.02 Million EUR 68.733%
Financière de Tubize SA 184.57 Thousand EUR 4677.938%
UCB SA 1.26 Billion EUR 100.666%
Valneva SE -64.51 Million EUR 86.903%
Vivoryon Therapeutics N.V. -28.35 Million EUR 70.199%